NOVAVAX, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.47 USD | 0.00% |
|
-5.10% | -6.88% |
Presenter SpeechJiale Song (Analysts)All right. Welcome, everyone. Day 2, 2023 Jefferies Healt...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. It has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid prototype COVID-19 vaccine (NVX-CoV2373 or prototype vaccine) and Nuvaxovid updated COVID-19 vaccine (NVX-CoV2601 or updated vaccine) (collectively, COVID-19 Vaccine). The Company is advancing the development of other vaccine candidates, including its COVID19-Influenza Combination (CIC) vaccine candidate and additional vaccine candidates. Its COVID-19 Vaccine and its other vaccine candidates incorporate the Companyâs proprietary Matrix-M adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.
Calendar
2024-05-09
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
4.47
USD
Average target price
15.4
USD
Spread / Average Target
+244.52%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -6.88% | 623M | |
| +23.37% | 46.71B | |
| +48.83% | 41.8B | |
| -0.94% | 41.52B | |
| -5.86% | 29.55B | |
| +11.29% | 25.78B | |
| -20.92% | 19.26B | |
| +3.20% | 12.14B | |
| -2.67% | 12.08B | |
| +30.23% | 11.98B |
- Stock Market
- Equities
- NVAX Stock
- News Novavax, Inc.
- Transcript : Novavax, Inc. Presents at Jefferies 2023 Global Healthcare Conference, Jun-08-2023 09